Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors

Anaplastic lymphoma kinase (ALK) rearrangements occur in ∼3%-6% of patients with advanced non-small-cell lung cancer (NSCLC). Small molecular drugs that effectively inhibit ALK gene have revolutionized the therapeutic paradigm for patients with ALK rearrangements, resulting in significant improvemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, F., Yang, Y., Zhang, L., Cheng, Y., Han, B., Lu, Y., Wang, C., Wang, Z., Yang, N., Fan, Y., Wang, L., Ma, Z., Yao, Y., Zhao, J., Dong, X., Zhu, B., Zhou, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225873/
https://www.ncbi.nlm.nih.gov/pubmed/37230029
http://dx.doi.org/10.1016/j.esmoop.2023.101560

Ejemplares similares

Ejemplares similares